Novo Sets Long-Term Targets Ahead of Semaglutide Patent Expirations Yahoo FinanceNovo shares slide as drugmaker lays out post-Wegovy growth strategy CNBCInvestors unconvinced by Novo’s latest growth plans FirstWord PharmaWegovy maker’s shares fall as blockbuster drugs plan disappoints The TimesWegovy maker Novo shares slump as management grilled on pricing, M&A Reuters
